Sana Biotech Rg

Sana Biotechnology uses HIP‑modified allogeneic cell platforms to target type‑1 diabetes, B‑cell autoimmunity, and oncology, with lead programs SG299 and SC291 in early‑stage trials and strategic licenses from Beam and Harvard.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 194
HQ: Seattle

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
SANA	Sana Biotech Rg Cap: 1.2B	EQUITY	NMS	USD	US7995661045	Active	📈